Skip Nav Destination
December 6 2013
In this Issue
Table of Contents
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Lisa K. Hicks,Harriet Bering,Kenneth R. Carson,Judith Kleinerman,Vishal Kukreti,Alice Ma,Brigitta U. Mueller,Sarah H. O'Brien,Marcelo Pasquini,Ravindra Sarode,Lawrence Solberg, Jr,Adam E. Haynes,Mark A. Crowther
A Fresh Look at Drug Approval: Moving Away from Tradition
Advances in Clotting Factors: From Bench to Bedside
Allogeneic Transplantation for High-Risk Myelodysplastic Syndromes and AML
Bad BUGS: Infections Causing Lymphoma
Changing Paradigms in Acute Lymphocytic Leukemia: From the Genome to the Patient
Chronic Lymphocytic Leukemia: A New Treatment Era Is Born
Chronic Myeloid Leukemia: Refining/Redefining the State of the Art
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond
Clinical Dilemmas in Acute Myeloid Leukemia
Clinical Production and Applications of Natural Killer Cell Immunotherapy
Congenital Bleeding Disorders
Disorders of Platelet Destruction
Finding Treatment for the Untreatable: The Power of Chemical Biology
Genomics in Hematology 101 for the Practicing Clinician
Graft Engineering and Adoptive Immunotherapy: Tackling Resistance
Hemoglobinopathies: Fresh Ideas for Management
HIV in Hematology: What's New?
Hodgkin Lymphoma: New and Old
Infectious Disease Complications Encountered by the Practicing Hematologist
Management of Sickle Cell Disease
Management of Thromboembolic Disease
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients
Myelodysplastic Syndromes: What Makes Therapy Effective?
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes
Myeloproliferative Diseases: It's Not ONLY about JAK
Non-Hodgkin Lymphomas I: Optimizing Therapy
Non-Hodgkin Lymphomas II: Breakthroughs in Treatment of High-Grade Lymphomas
Pediatric Hematology: Insights Applicable to All!
Sports Medicine in Hematology
Trauma-Induced Coagulopathy: A Clinical and Scientific Perspective
Updates in Aggressive Thrombotic Disease
Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?
Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2012;2012:19–27.
Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology Am Soc Hematol Educ Program. 2012;2012:65–73.
Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:88–96.
Cover: Blood cells. Colored scanning electron micrograph (SEM) of red blood cells and an aggregate of platelets (yellow). Magnification: x4000 when printed at 10 centimeters wide. © Steve Gschmeissner/Science Photo Library/Corbis.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board